You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

famitinib

Showing 1 - 21 of 21
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Famitinib
  • +2 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Healthy Subjects Trial (Famitinib)

Not yet recruiting
  • Healthy Subjects
  • Famitinib
  • (no location specified)
Jul 25, 2022

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • SHR-1210
  • Famitinib
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Advanced Breast Cancer, Metastatic Breast Cancer Trial in Tianjin (SHR6390, famitinib)

Recruiting
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
Apr 6, 2022

Solid Tumor Trial in Shanghai (Camrelizumab, Famitinib)

Active, not recruiting
  • Solid Tumor
  • Shanghai, Shanghai, China
    Fudan University Zhongshan Hospital
Feb 9, 2022

Advanced NSCLC Trial in Yangzhou (camrelizumab + famitinib, famitinib, docetaxel)

Recruiting
  • Advanced NSCLC
  • camrelizumab + famitinib
  • +2 more
  • Yangzhou, Jiangsu, China
    Subei People's Hospital of Jiangsu Province
Jan 11, 2022

Metastatic Breast Cancer Trial in Zhengzhou (Famitinib, SHR6390, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • Famitinib
  • +2 more
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jan 25, 2022

NSCLC Trial in Shanghai (Camrelizumab, Famitinib)

Not yet recruiting
  • NSCLC
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Aug 5, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1701, Famitinib)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Hospital of Guangzhou Sun Yat-sen University
Aug 23, 2021

Solid Tumor Trial in China (SHR-1701, Famitinib)

Recruiting
  • Solid Tumor
  • SHR-1701
  • Famitinib
  • Hefei, Anhui, China
  • +15 more
Jan 11, 2022

Intrahepatic Cholangiocarcinoma Trial (Famitinib)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • Famitinib
  • (no location specified)
Jun 16, 2021

Sarcomatoid Carcinoma of Lung Trial (Camrelizumab, Famitinib)

Not yet recruiting
  • Sarcomatoid Carcinoma of Lung
  • (no location specified)
May 12, 2021

Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)

Recruiting
  • Breast Cancer
  • Metastatic Cancer
  • Shanghai, Shanghai, China
    Cancer Hospital Affiliated to Fudan University
Jul 22, 2022

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Effect of Drugs, Progression, Pediatric Cancer Trial in Beijing (Famitinib, Ifosfamide, Camrelizumab)

Withdrawn
  • Effect of Drugs
  • +2 more
  • Famitinib
  • +2 more
  • Beijing, Beijing, China
    Lu Xie
May 15, 2020

Colorectal Cancer Metastatic, Colorectal Cancer Recurrent Trial in China (Famitinib, Placebo)

Completed
  • Colorectal Cancer Metastatic
  • Colorectal Cancer Recurrent
  • Famitinib
  • Placebo
  • Hefei, Anhui, China
  • +43 more
Dec 21, 2020

NSCLC (NSCLC) Trial in Guangzhou, Shanghai (Famitinib, Placebo)

Suspended
  • Non-Small Cell Lung Cancer (NSCLC)
  • Famitinib
  • Placebo
  • Guangzhou, Guangdong, China
  • +1 more
Oct 31, 2019

Gastroenteropancreatic Neuroendocrine Tumor Trial in Beijing (Famitinib)

Terminated
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Famitinib
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Jan 17, 2019

Gastrointestinal Stromal Tumor Trial in Nanjing (Famitinib)

Unknown status
  • Gastrointestinal Stromal Tumor
  • Famitinib
  • Nanjing, Jiangsu, China
    Nanjing Bayi Hospital
Apr 16, 2018

Renal Cell Cancer, Metastatic Renal Cell Cancer Trial in Beijing (Famitinib, Sunitinib)

Completed
  • Renal Cell Cancer
  • Metastatic Renal Cell Cancer
  • Beijing, China
    Cancer Institute and Hospital Chinese Academy of Medical Science
May 1, 2018

Locally Advanced Nasopharyngeal Carcinoma Trial in Guangzhou (Famitinib, Cisplatin, radiation(IMRT))

Completed
  • Locally Advanced Nasopharyngeal Carcinoma
  • Famitinib
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Cancer Center, Sun Yet-sen Unive
Apr 16, 2018